<a href="https://www.fiercebiotech.com/biotech/agios-next-gen-pk-drug-fails-blood-cancer-study-scd-ambitions-undimmed" hreflang="en">Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed</a>
Agios Pharmaceuticals' next-gen pyruvate kinase activator, tebapivat, failed a phase 2 study for treating lower-risk myelodysplastic syndromes, missing its primary endpoint. However, the company remains optimistic about its potential in treating sickle cell disease, with ongoing trials planned for later this year.
Agios Pharmaceuticals' persistence in developing their PK activator, tebapivat, despite its failure in a phase 2b trial for lower-risk myelodysplastic syndromes, highlights the potential for pivoting research efforts towards more promising indications such as sickle cell disease (SCD). This strategic focus shift can provide an investment opportunity, particularly as the SCD trial results are expected in the second half of the year, which could significantly impact Agios' market positioning and stock valuation.